3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Polycythemia Vera
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Thrombocythemia, Essential
5
Philadelphia Chromosome
2
Myeloproliferative Disorders
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Melanoma
1
Leukemia
1
Carcinoma, Renal Cell
1
Blast Crisis
1
Interventions
Cyclophosphamide
53
fludarabine phosphate
52
Peripheral Blood Stem Cell Transplantation
52
Busulfan
39
Tacrolimus
36
Mycophenolic Acid
32
Methotrexate
31
Cyclosporine
31
Antilymphocyte Serum
31
Filgrastim
26
Whole-Body Irradiation
25
Cytarabine
24
Radiotherapy
21
Methylprednisolone
20
Cord Blood Stem Cell Transplantation
18
Melphalan
17
Imatinib Mesylate
17
Etoposide
16
Flow Cytometry
12
Thiotepa
11
fludarabine
10
Dasatinib
10
Therapeutics
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
nilotinib
8
sargramostim
7
Psychiatric Rehabilitation
7
Decitabine
7
Prednisone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blast Crisis
×
peginterferon alfa-2a
×
Myeloid
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled